Associations between PD-L1 expression and clinicopathological characteristics
| Subgroup | N | T-PD-L1 (5% cut-off value) | I-PD-L1 (1% cut-off value) | ||||
| Negative | Positive | P value | Negative | Positive | P value | ||
| Overall | 96 | 56 | 40 | 50 | 46 | ||
| Gender | |||||||
| Female | 6 (5.3) | 3 (3.8) | 0.859 | 3 (4.7) | 6 (4.3) | 0.405 | |
| Male | 50 (50.8) | 37 (36.3) | 47 (45.3) | 40 (41.7) | |||
| Age (years) | |||||||
| ≤75 | 26 (27.4) | 21 (19.6) | 0.557 | 23 (24.5) | 24 (22.5) | 0.545 | |
| ＞75 | 30 (28.6) | 19 (20.4) | 27 (25.5) | 22 (23.5) | |||
| Tumour differentiation | |||||||
| Single differentiation | 51 (49.0) | 33 (35.0) | 0.211 | 41 (43.8) | 43 (40.3) | 0.165 | |
| With other components | 5 (7.0) | 7 (5.0) | 9 (6.3) | 3 (5.8) | |||
| Tumour depth | |||||||
| T1 | 10 (8.8) | 5 (6.3) | 0.169 | 7 (7.8) | 8 (7.2) | 0.865 | |
| T2 | 40 (37.9) | 25 (27.1) | 34 (33.9) | 31 (31.1) | |||
| T3/4 | 6 (9.3) | 10 (6.7) | 9 (8.3) | 7 (7.7) | |||
| LN metastasis | |||||||
| Absent | 50 (48.4) | 33 (34.6) | 0.338 | 42 (43.2) | 41 (39.8) | 0.463 | |
| Present | 6 (7.6) | 7 (5.4) | 8 (6.8) | 5 (6.2) | |||
| TNM stage | |||||||
| I–II | 46 (41.4) | 25 (29.6) | 0.031 | 36 (37.0) | 35 (34.0) | 0.649 | |
| III–IV | 10 (14.6) | 15 (10.4) | 14 (13.0) | 11 (12.0) | |||
| TILs | |||||||
| Absent | 31 (22.8) | 8 (16.3) | 0.001 | 33 (20.3) | 6 (18.7) | ＜0.001 | |
| Present | 25 (33.3) | 32 (23.8) | 17 (29.7) | 40 (27.3) | |||
| T-PD-L1 (5% cut-off value) | |||||||
| Negative | 34 (29.2) | 22 (26.8) | 0.045 | ||||
| Positive | 16 (20.8) | 24 (19.2) | |||||
| I-PD-L1 (1% cut-off value) | |||||||
| Negative | 34 (29.2) | 16 (20.8) | 0.045 | ||||
| Positive | 22 (26.8) | 24 (19.2) | |||||
TILs, tumour infiltrating lymphocytes.